Research progress on laboratory diagnostic techniques for drug-resistant tuberculosis

doi:10.3969/j.issn.1673-8640.2024.02.020

Abstract

Abstract:

Tuberculosis(TB) is one of the most serious global public health threats at present. Drug-resistant tuberculosis(DR-TB) is the focus and difficulty of TB prevention and treatment. This review focuses on the research progress of laboratory diagnostic techniques for DR-TB in terms of phenotypic drug susceptibility testing，including susceptibility testing for anti-TB agents using solid or liquid media and minimum inhibitory concentration methods. Molecular drug susceptibility testing includes GeneXpert MTB/RIF，line probe assay，gene chip method，fluorescence polymerase chain reaction(PCR) melting curve method，FluoroType MTBDR，Xpert MTB/XDR，nucleic acid mass spectrometry system and whole genome sequencing. The aim of this review is to provide a reference for the early diagnosis of DR-TB.

Key words: Drug-resistant tuberculosis, Phenotypic drug susceptibility test, Molecular drug susceptibility testing

CLC Number:

LI Ningdi, JIANG Yuan. Research progress on laboratory diagnostic techniques for drug-resistant tuberculosis[J]. Laboratory Medicine, 2024, 39(2): 203-208.

References 40

[1]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志, 2012, 34(8):485-508.
[2]	World Health Organization. Global tuberculosis report[EB/OL]. https://www.who.int/teams/global-tuberculosis-programme/data.
[3]	Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020[S]. Geneva: World Health Organization, 2021.
[4]	WHO operational handbook on tuberculosis.Module 4:treatment-drug-resistant tuberculosis treatment[S]. Geneva: World Health Organization, 2020.
[5]	KHAN M A, BILAL W, ASIM H, et al. MDR-TB in Pakistan:challenges,efforts,and recommendations[J]. Ann Med Surg(Lond), 2022, 79:104009.
[6]	WAKJIRA M K, SANDY P T, MAVHANDU-MUDZUSI A H. Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia[J]. PLoS One, 2022, 17(2):e0262318. DOI URL
[7]	YANG X, YUAN Y, PANG Y, et al. The burden of MDR/XDR tuberculosis in coastal plains population of China[J]. PLoS One, 2015, 10(2):e0117361. DOI URL
[8]	LECAI J, MIJITI P, CHUANGYUE H, et al. Predictors and trends of MDR/RR-TB in Shenzhen China:a retrospective 2012-2020 period analysis[J]. Infect Drug Resist, 2021, 14:4481-4491. DOI URL
[9]	张学志, 陈丽, 葛亚萍, 等. 比例法与绝对浓度法测试结核分枝杆菌药物敏感性探讨[J]. 中国防痨杂志, 2009, 31(3):164-166.
[10]	张娟, 蒋俊, 张红, 等. MGIT960与罗氏培养法在结核分枝杆菌培养及药敏试验中的比对分析[J]. 中国防痨杂志, 2011, 33(6):361-365.
[11]	Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins(rifampicin,rifabutin and rifapentine)[S]. Geneva: World Health Organization, 2021.
[12]	HELB D, JONES M, STORY E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand,near-patient technology[J]. J Clin Microbiol, 2010, 48(1):229-237. DOI URL
[13]	冯菁楠, 高乐, 孙一鑫, 等. Xpert®MTB/RIF对我国人群活动性肺结核和利福平耐药肺结核诊断准确性的meta分析[J]. 北京大学学报(医学版), 2021, 53(2):320-326.
[14]	赵颖, 嘎松卓嘎, 次白, 等. Xpert MTB/RIF技术在高海拔地区结核病诊断中的应用[J]. 检验医学, 2021, 36(9):947-950. DOI
[15]	GIDADO M, NWOKOYE N, OGBUDEBE C, et al. Assessment of GeneXpert MTB/RIF performance by type and level of health-care facilities in Nigeria[J]. Niger Med J, 2019, 60(1):33-39. DOI URL
[16]	MAKAMURE B, MAKUMBIROFA S, BANDASON T, et al. A suggested algorithm for detection of multi drug-resistant tuberculosis in Zimbabwe[J]. J Infect Dev Ctries, 2017, 11(8):611-618. DOI URL
[17]	DORMAN S E, SCHUMACHER S G, ALLAND D, et al. Xpert MTB/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance:a prospective multicentre diagnostic accuracy study[J]. Lancet Infect Dis, 2018, 18(1):76-84. DOI URL
[18]	陈琛, 马远征. 分子线性探针测定法在结核病诊断中的研究进展[J]. 中国防痨杂志, 2016, 38(3):218-221.
[19]	BAI Y, WANG Y, SHAO C, et al. GenoType MTBDRplus assay for rapid detection of multidrug resistance in Mycobacterium tuberculosis:a meta-analysis[J]. PLoS One, 2016, 11(3):e0150321. DOI URL
[20]	江丽娜, 穆成, 孙蕊, 等. 二代线性探针技术在结核分枝杆菌耐药性检测中的价值[J]. 中国防痨杂志, 2019, 41(11):1184-1190.
[21]	THERON G, PETER J, RICHARDSON M, et al. GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs[J]. Cochrane Database Syst Rev, 2016, 9(9):CD010705.
[22]	李强, 夏辉, 欧喜超, 等. 应用线性探针技术与传统药敏试验检测耐药结核病的成本比较[J]. 中国防痨杂志, 2013, 35(3):187-190.
[23]	SINGLA N, SATYANARAYANA S, SACHDEVA K S, et al. Impact of introducing the line probe assay on time to treatment initiation of MDR-TB in Delhi,India[J]. PLoS One, 2014, 9(7):e102989. DOI URL
[24]	PANG Y, XIA H, ZHANG Z, et al. Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis[J]. J Clin Microbiol, 2013, 51(6):1707-1713. DOI URL
[25]	PANG Y, DONG H, TAN Y, et al. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China[J]. Sci Rep, 2016, 6:25330. DOI PMID
[26]	HU S, LI G, LI H, et al. Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis[J]. J Clin Microbiol, 2014, 52(5):1644-1652. DOI URL
[27]	Update on the use of nucleic acid amplification tests to detect TB and drug-resistant TB:rapid communication[S]. Geneva: World Health Organization, 2021.
[28]	HILLEMANN D, HAASIS C, ANDRES S, et al. Validation of the FluoroType MTBDR assay for detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates[J]. J Clin Microbiol, 2018, 56(6):e00072-18.
[29]	DE VOS M, DERENDINGER B, DOLBY T, et al. Diagnostic accuracy and utility of FluoroType MTBDR,a new molecular assay for multidrug-resistant tuberculosis[J]. J Clin Microbiol, 2018, 56(9):e00531.
[30]	DIPPENAAR A, DERENDINGER B, DOLBY T, et al. Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance[J]. Clin Microbiol Infect, 2021, 27(9):1351.e1-1351.e4. DOI URL
[31]	TRUDEN S, SODJA E, ŽOLNIR-DOVČ M. Drug-resistant tuberculosis on the balkan peninsula:determination of drug resistance mechanisms with Xpert MTB/XDR and whole-genome sequencing analysis[J]. Microbiol Spectr, 2023, 11(2):e0276122. DOI URL
[32]	CAO Y, PARMAR H, GAUR R L, et al. Xpert MTB/XDR:a 10-color reflex assay suitable for point-of-care settings to detect isoniazid,fluoroquinolone,and second-line-injectable-drug resistance directly from Mycobacterium tuberculosis-positive sputum[J]. J Clin Microbiol, 2021, 59(3):e02314-e02320.
[33]	中国人民解放军总医院第八医学中心结核病医学部, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会. 核酸基质辅助激光解吸电离飞行时间质谱技术在结核病和非结核分枝杆菌病诊断中的临床应用专家共识[J]. 中国防痨杂志, 2023, 45(6):543-558.
[34]	WU X, TAN G, YANG J, et al. Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI-TOF-MS[J]. Int J Infect Dis, 2022, 121:47-54. DOI URL
[35]	马俊, 沙巍. 结核病分子生物学诊断新技术的研究进展[J]. 同济大学学报(医学版), 2022, 43(4):579-585.
[36]	LIU D, HUANG F, ZHANG G, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China[J]. Clin Microbiol Infect, 2022, 28(5):731.e9-731.e15. DOI URL
[37]	王玉峰, 逄宇. 世界卫生组织《结核分枝杆菌耐药相关基因突变目录及其临床应用指南》解读[J]. 中国临床新医学, 2022, 15(10):900-906.
[38]	Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance[S]. Geneva: World Health Organization, 2021.
[39]	夏辉, 赵雁林. 世界卫生组织《关于更新使用结核分枝杆菌及其耐药性核酸扩增检测技术的建议》的启示[J]. 中国防痨杂志, 2021, 43(8):761-765.
[40]	DENG Y, MA Z, SU B, et al. Accuracy of the innowaveDX MTB/RIF test for detection of Mycobacterium tuberculosis and rifampicin resistance:a prospective multicentre study[J]. Emerg Microbes Infect, 2023, 12(1):2151382. DOI URL